See more : Godfrey Phillips India Limited (GODFRYPHLP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Quantum Genomics Société Anonyme (QNNTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quantum Genomics Société Anonyme, a leading company in the Biotechnology industry within the Healthcare sector.
- Alpha Partners Technology Merger Corp. (APTM) Income Statement Analysis – Financial Results
- Ceylon Graphite Corp. (CYL.V) Income Statement Analysis – Financial Results
- Riskmonster.com (3768.T) Income Statement Analysis – Financial Results
- JX Luxventure Limited (LLL) Income Statement Analysis – Financial Results
- Ningbo Joyson Electronic Corp. (600699.SS) Income Statement Analysis – Financial Results
Quantum Genomics Société Anonyme (QNNTF)
About Quantum Genomics Société Anonyme
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.80K | 2.52M | 3.14M | 1.83M | 1.55M | 3.69K | 0.00 | 0.00 | 144.14K | 324.30K | 17.40K | 19.20K |
| Cost of Revenue | 1.44M | 29.50M | 20.34M | 16.73M | 12.03K | 19.02K | 25.87K | 3.87M | 2.77M | 1.32M | 1.09M | 955.41K |
| Gross Profit | -1.42M | -26.99M | -17.21M | -14.91M | 1.53M | -15.33K | -25.87K | -3.87M | -2.62M | -999.64K | -1.07M | -936.21K |
| Gross Profit Ratio | -7,169.57% | -1,073.02% | -548.31% | -814.93% | 99.22% | -415.95% | 0.00% | 0.00% | -1,819.12% | -308.24% | -6,150.93% | -4,876.10% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 4.87M | 8.00M | 4.55M | 2.28M | 1.56M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 16.71M | 12.30M | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 1.32M | 1.09M | 955.41K |
| Selling & Marketing | 0.00 | 0.00 | -14.09M | -10.39M | 0.00 | 0.00 | 0.00 | 0.00 | -1.01M | -21.10K | 0.00 | 0.00 |
| SG&A | 1.58M | 2.74M | 2.62M | 1.91M | 5.93M | 5.34M | 5.66M | 48.09K | 1.60M | 1.30M | 1.09M | 955.41K |
| Other Expenses | 139.35K | 1.70M | -290.00K | -17.00K | 56.53K | -239.02K | -48.88K | -13.88K | -64.05K | -43.12K | -255.38K | -830.69K |
| Operating Expenses | 1.72M | 479.95K | 2.91M | 1.93M | 10.75M | 13.58M | 10.27M | 2.34M | 1.66M | 1.52M | 832.28K | 124.73K |
| Cost & Expenses | 3.16M | 29.98M | 23.25M | 18.66M | 10.76M | 13.60M | 10.29M | 6.22M | 4.43M | 2.85M | 1.92M | 1.08M |
| Interest Income | 0.00 | 17.50K | 39.00K | 6.00K | 7.00K | 10.54K | 27.85K | 30.68K | 192.86K | 19.39K | 153.00 | 3.61K |
| Interest Expense | 21.40K | 17.67K | 46.00K | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 222.22K | 19.81K | 11.99K | 18.61K |
| Depreciation & Amortization | 263.77K | 263.77K | 390.00K | 137.00K | 12.03K | 19.02K | 25.87K | 26.95K | 24.21K | 15.04K | 9.00K | 12.00K |
| EBITDA | -2.87M | -29.82M | -19.41M | -14.67M | -10.61M | -13.55M | -10.27M | -6.19M | -4.26M | -2.45M | -1.89M | -1.05M |
| EBITDA Ratio | -14,515.46% | -1,185.63% | -628.52% | -912.79% | -694.76% | -368,396.09% | 0.00% | 0.00% | -2,973.43% | -740.82% | -10,870.25% | -5,454.15% |
| Operating Income | -3.14M | -30.08M | -20.11M | -16.83M | -10.76M | -13.60M | -10.29M | -6.22M | -4.31M | -2.42M | -1.90M | -1.06M |
| Operating Income Ratio | -15,847.92% | -1,196.12% | -640.95% | -920.28% | -695.54% | -368,912.10% | 0.00% | 0.00% | -2,990.22% | -745.46% | -10,934.16% | -5,525.72% |
| Total Other Income/Expenses | -68.12K | 2.60M | -662.97K | -1.46M | 134.34K | 149.68K | -239.28K | 16.70K | -168.06K | -124.28K | -11.84K | -16.87K |
| Income Before Tax | -3.21M | -27.48M | -19.85M | -18.29M | -10.63M | -13.45M | -10.53M | -6.20M | -4.48M | -2.54M | -1.91M | -1.08M |
| Income Before Tax Ratio | -16,192.05% | -1,092.80% | -632.57% | -1,000.00% | -686.85% | -364,851.68% | 0.00% | 0.00% | -3,106.82% | -783.78% | -11,002.19% | -5,613.56% |
| Income Tax Expense | -34.43K | 2.55M | -2.49M | -2.07M | -1.55M | -1.46M | -1.15M | -957.93K | 713.84K | 334.95K | -373.98K | -233.93K |
| Net Income | -3.17M | -24.94M | -17.36M | -16.22M | -9.08M | -11.99M | -9.38M | -5.24M | -3.76M | -2.21M | -1.54M | -843.40K |
| Net Income Ratio | -16,018.12% | -991.45% | -553.19% | -887.04% | -586.84% | -325,286.35% | 0.00% | 0.00% | -2,611.57% | -680.49% | -8,858.79% | -4,392.68% |
| EPS | -0.09 | -0.72 | -0.64 | -0.79 | -0.50 | -0.76 | -0.86 | -0.63 | -0.54 | -0.46 | -0.37 | -0.01 |
| EPS Diluted | -0.09 | -0.72 | -0.64 | -0.79 | -0.50 | -0.76 | -0.86 | -0.63 | -0.54 | -0.46 | -0.36 | -0.01 |
| Weighted Avg Shares Out | 34.86M | 34.53M | 26.96M | 20.41M | 17.98M | 15.72M | 10.93M | 8.35M | 6.91M | 4.81M | 4.13M | 68.19M |
| Weighted Avg Shares Out (Dil) | 34.86M | 34.53M | 26.96M | 20.41M | 17.98M | 15.72M | 10.93M | 8.35M | 6.91M | 4.81M | 4.25M | 68.19M |
Quantum Genomics and its Partners Reach a New Stage of Development in Asia
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat
Source: https://incomestatements.info
Category: Stock Reports